Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/182930
Title: | Sustained low disease activity measured by ASDAS slow radiographic spinal progression in axial spondyloarthritis patients treated with TNF-inhibitors: data from REGISPONSERBIO |
Author: | Llop, Maria Moreno, Mireia Navarro Compán, Victoria Juanola, Xavier Miguel, Eugenio de Almodóvar, Raquel Cuende Quintana, Eduardo Sanz Sanz, Jesús Beltrán, Emma Ruiz Montesinos, M. Dolores Calvet, Joan Berenguer Llergo, Antoni Gratacós, Jordi Zarco Montejo, Pedro Joven, Beatriz Almirall, Míriam Fernandez Espartero, Ma. Cruz Batlle Gualda, Enrique Campos, Cristina Collantes Estevez, Eduardo Font, Pilar Clavaguera Poch, Teresa Linares Ferrando, Luis F. Rodríguez Lozano, Carlos Yoldi, Beatriz Regisponserbio Group |
Keywords: | Espondiloartropaties Medicaments Spondyloarthropathies Drugs |
Issue Date: | 21-Jan-2022 |
Publisher: | Springer Science and Business Media LLC |
Abstract: | Background To evaluate the influence of the disease activity on radiographic progression in axial spondyloarthritis (axSpA) patients treated with TNF inhibitors (TNFi). Methods The study included 101 axSpA patients from the Spanish Register of Biological Therapy in Spondyloarthritides (REGISPONSERBIO), which had clinical data and radiographic assessment available. Patients were classified into 2 groups based on the duration of TNFi treatment at baseline: (i) long-term treatment (>= 4 years) and (ii) no long-term treatment (< 4 years). Radiographs were scored by two readers according to the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) with known chronology. Disease activity differences between patients' groups at each time point were assessed using a linear mixed-effect model. Results Radiographic progression was defined as an increase in >= 2 mSASSS units. At inclusion, approximately half of the patients (45.5%) were receiving long-term treatment with TNFi (>= 4 years). In this group of subjects, a significant difference in averaged Ankylosing Spondylitis disease Activity Score (ASDAS) across follow-up was found between progressors and non-progressors (2.33 vs 1.76, p=0.027, respectively). In patients not under long-term TNFi treatment (54.5%) though, no significant ASDAS differences were observed between progressors and non-progressors until the third year of follow-up. Furthermore, no significant differences were found in progression status, when disease activity was measured by Bath Ankylosing spondylitis Disease Activity Index (BASDAI) and C reactive protein (CRP). Conclusions Patients on long-term TNFi treatment with a mean sustained low disease activity measures by ASDAS presented lower radiographic progression than those with active disease. |
Note: | Reproducció del document publicat a: https://doi.org/10.1186/s13075-021-02695-5 |
It is part of: | Arthritis Research & Therapy, 2022, vol 24, num 1 |
URI: | http://hdl.handle.net/2445/182930 |
Related resource: | https://doi.org/10.1186/s13075-021-02695-5 |
ISSN: | 1478-6362 |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
s13075-021-02695-5.pdf | 958.02 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License